Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
Acknowledgements: Dr. Abdel Jawad is currently supported by the National Heart, Lung, and Blood Institute under Award Number T32H110837. The contents of this project are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences; the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the Department of Health and Human Services.
Publication Details
- Journal
- Apollo (University of Cambridge)
- Published
- 2025-04-28
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00